Allogene Therapeutics Inc (ALLO)

05:10 AM

What are the technical indicators suggesting about Allogene Therapeutics Inc.High-yield growth strategies - jammulinksnews.com

05:10 AM

04:20 AM

When is Allogene Therapeutics Inc. stock expected to show significant growthInvest confidently with market-leading analysis - jammulinksnews.com

04:20 AM

03:40 AM

How does Allogene Therapeutics Inc. compare to its industry peersMaximize your portfolio’s growth potential - jammulinksnews.com

03:40 AM

06:44 AM

Is it the right time to buy Allogene Therapeutics Inc. stockJaw-dropping returns - jammulinksnews.com

06:44 AM

05:11 AM

Is Allogene Therapeutics Inc. stock overvalued or undervaluedMaximize returns with disciplined investment techniques - jammulinksnews.com

05:11 AM

04:00 AM

What drives Allogene Therapeutics Inc. stock priceStrong return on assets - jammulinksnews.com

04:00 AM

12:43 PM

What are Allogene Therapeutics Inc. company’s key revenue driversUnstoppable profit momentum - jammulinksnews.com

12:43 PM

Aug 02, 2025

How many analysts rate Allogene Therapeutics Inc. as a “Buy”Access daily stock market expert updates - jammulinksnews.com

Aug 02, 2025

Aug 02, 2025

What is the dividend policy of Allogene Therapeutics Inc. stockGet real-time alerts on high-potential stocks - jammulinksnews.com

Aug 02, 2025

Aug 02, 2025

What are the latest earnings results for Allogene Therapeutics Inc.Jaw-dropping returns - jammulinksnews.com

Aug 02, 2025

Aug 01, 2025

How volatile is Allogene Therapeutics Inc. stock compared to the marketBeginner Investor Report With Low Risk - jammulinksnews.com

Aug 01, 2025

Aug 01, 2025

Allogene Therapeutics Faces Market Volatility Amid Financial Challenges - StocksToTrade

Aug 01, 2025

Aug 01, 2025

Allogene Resets Clinical Course After Patient Death In Lymphoma Study - Benzinga

Aug 01, 2025

Aug 01, 2025

Regeneron cancer bispecific rejected again; Allogene discloses trial death - BioPharma Dive

Aug 01, 2025

Aug 01, 2025

Allogene Therapeutics updates ALPHA3 trial protocol following safety event By Investing.com - Investing.com India

Aug 01, 2025

Aug 01, 2025

Allogene Therapeutics updates ALPHA3 trial protocol following safety event - Investing.com

Aug 01, 2025

Aug 01, 2025

Allogene Therapeutics Adjusts ALPHA3 Trial After Adverse Event - TipRanks

Aug 01, 2025

Aug 01, 2025

RENT Form 144: Insider plans to sell 262 shares worth $1.49k | ALLO SEC FilingForm 8-K - Stock Titan

Aug 01, 2025

Aug 01, 2025

Allogene Therapeutics Announces Selection of Standard FC Lymphodepletion Regimen in ALPHA3 Study Following Consultation with FDA and Safety Board - Quiver Quantitative

Aug 01, 2025

Aug 01, 2025

Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma - The Manila Times

Aug 01, 2025

Aug 01, 2025

Allogene says lymphodepletion drug caused patient death, changes CAR-T study design - Endpoints News

Aug 01, 2025

Jul 31, 2025

Allogene Therapeutics shares rise 2.33% premarket after Robbins LLP class action filing. - AInvest

Jul 31, 2025

Jul 30, 2025

Understanding Allogene Therapeutics Inc.’s price movementCommunity Entry Consensus Trade Ideas Shared - metal.it

Jul 30, 2025

Jul 29, 2025

Allogene Therapeutics Inc. Trading Near Value Zone — Recovery AheadWatchlist for Low Risk High Return Stocks Updated - metal.it

Jul 29, 2025

Jul 29, 2025

RSI Crosses Above 30 for Allogene Therapeutics Inc. — Reversal in SightLow Volatility Stable Growth Picks Rank High - metal.it

Jul 29, 2025

Jul 29, 2025

Published on: 2025-07-29 12:47:04 - metal.it

Jul 29, 2025

Jul 29, 2025

CAR-T Cell Therapy Market is projected to grow to US$ 20.4 billion - openPR.com

Jul 29, 2025

Jul 28, 2025

Allogene Therapeutics Inc. Forms Bullish Flag — Upside AheadLow Drawdown Real Time Trading Tips Shared - metal.it

Jul 28, 2025

Jul 28, 2025

What is the risk reward ratio of investing in Allogene Therapeutics Inc. stockBest Dividend Forecasts To Watch Now - jammulinksnews.com

Jul 28, 2025

Jul 28, 2025

Does Allogene Therapeutics Inc. stock perform well during market downturnsPre Market Ideas For Beginners - jammulinksnews.com

Jul 28, 2025

Jul 28, 2025

How does Allogene Therapeutics Inc. generate profit in a changing economyAchieve breakthrough financial results today - jammulinksnews.com

Jul 28, 2025

Jul 27, 2025

What institutional investors are buying Allogene Therapeutics Inc. stockBuild a diversified portfolio for steady growth - jammulinksnews.com

Jul 27, 2025

Jul 25, 2025

Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update - ADVFN Brasil

Jul 25, 2025

Jul 25, 2025

Allogene’s ALLO-329: A New Frontier in Autoimmune Disease Treatment - TipRanks

Jul 25, 2025

Jul 25, 2025

Is Allogene Therapeutics Inc. a good long term investmentPhenomenal capital appreciation - PrintWeekIndia

Jul 25, 2025

Jul 25, 2025

Global Allogeneic Cell Therapy Market to grow at 25% CAGR on rising demand and trials by 2030 - PharmiWeb.com

Jul 25, 2025

Jul 25, 2025

Is Allogene Therapeutics Inc. stock a good hedge against inflationConsistent triple returns - jammulinksnews.com

Jul 25, 2025

Jul 25, 2025

Allogene Therapeutics Inc. Stock Analysis and ForecastExplosive trading growth - PrintWeekIndia

Jul 25, 2025

Jul 24, 2025

Multiple Insiders Sold Allogene Therapeutics Shares Presenting Weak Signs For Investors - 富途牛牛

Jul 24, 2025

Jul 23, 2025

What analysts say about Allogene Therapeutics Inc. stockRapid return acceleration - Autocar Professional

Jul 23, 2025

Jul 23, 2025

High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - Benzinga

Jul 23, 2025